Important To Health News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nyrada Inc (ASX:NYR) 57% Reduction in Total Cholesterol from Nyrada s NYX-PCSK9i In Vivo Study
  
57% Reduction in Total Cholesterol from Nyrada s NYX-PCSK9i In Vivo StudySydney, Dec 21, 2020 AEST (ABN Newswire) - Nyrada Inc (
ASX:NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholesterolemia (high cholesterol).
- Very encouraging preliminary in vivo efficacy results for Nyrada s oral PCSK9 inhibitor NYX-PCSK9i, showing a 57% reduction in total cholesterol
- Provides proof-of-concept in a specialised mouse model which has demonstrated high predictability of human cholesterol metabolism and cardiovascular health outcomes ....

New South Wales , Sanofi Regeneron , James Bonnar , Praluentr Sanofi Regeneron , Gilles Lambert , Nyrada Inc , University Of La Reunion Medical School , Important To Health , Total Cholesterol , Nyrada Scientific Advisory Board Member , Cell Biology , Current Treatments , Specialised Transgenic Mouse Model , புதியது தெற்கு வேல்ஸ் , கில்லஸ் ல்யாம்‌பர்ட் , பல்கலைக்கழகம் ஆஃப் லா மீண்டும் இணைதல் மருத்துவ பள்ளி , முக்கியமான க்கு ஆரோக்கியம் , மொத்தம் கொழுப்பு , செல் உயிரியல் , தற்போதைய சிகிச்சைகள் ,